Targeting Cancer with Telomerase

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1203-1205

  Hahn, William C ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; IMATINIB; RITUXIMAB; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRASTUZUMAB;

APOPTOSIS; BYSTANDER EFFECT; CANCER CELL; CELL IMMORTALIZATION; CELL KILLING; DNA FLANKING REGION; DNA MICROARRAY; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; NOTE; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; TELOMERE;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE;

EID: 1642333982     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0060     Document Type: Note

References (25)

1. Blackburn, E. H. Telomere states and cell fates. Nature (Lond.), 408: 53-56, 2000.
2. Hahn, W. C., and Weinberg, R. A. Modelling the molecular circuitry of cancer. Nature Rev. Cancer, 2: 331-341, 2002.
3. Greider, C. W., and Blackburn, E. H. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell, 51: 887-898, 1987.
4. Feng, J., Funk, W. D., Wang, S. S., Weinrich, S. L., Avilion, A. A., Chiu, C. P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., L, Le, S., West, M. D., Harley, C. B., Andrews, W. H., Greider, C. W., and Villeponteau, B. The RNA component of human telomerase. Science (Wash. DC), 269: 1236-1241, 1995.
5. Nakamura, T. M., and Cech, T. R. Reversing time: origin of telomerase. Cell, 92: 587-590, 1998.
6. Masutomi, K., Yu, E. Y., Khurts, S., Ben-Porath, I., Currier, J. L., Metz, G. B., Brooks, M. W., Kaneko, S., Murakami, S., DeCaprio, J. A., Weinberg, R. A., Stewart, S. A., and Hahn, W. C. Telomerase maintains telomere structure in normal human cells. Cell, 114: 241-253, 2003.
7. Harley, C. B., Kim, N. W., Prowse, K. R., Weinrich, S. L., Hirsch, K. S., West, M. D., Bacchetti, S., Hirte, H. W., Counter, C. M., Greider, C. W., Piatyszek, M. A., Wright, W. E., and Shay, J. W. Telomerase, cell immortality, and cancer. Cold Spring Harb. Symp. Quant. Biol., 59: 307-315, 1994.
8. Shay, J. W., and Wright, W. E. Telomerase activity in human cancer. Curr. Opin. Oncol., 8: 66-71, 1996.
9. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. Science (Wash. DC), 266: 2011-2015, 1994.
10. Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., and Weinberg, R. A. Creation of human tumor cells with defined genetic elements. Nature (Lond.), 400: 464-468, 1999.
11. Hahn, W. C., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Kurachi, A., Beijersbergen, R. L., Knoll, J. H., Meyerson, M., and Weinberg, R. A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med., 5: 1164-1170, 1999.
12. Asai, A., Oshima, Y., Yamamoto, Y., Uochi, T. A., Kusaka, H., Akinaga, S., Yamashita, Y., Pongracz, K., Pruzan, R., Wunder, E., Piatyszek, M., Li, S., Chin, A. C., Harley, C. B., and Gryaznov, S. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res., 63: 3931-3939, 2003.
13. Herbert, B., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., and Corey, D. R. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA, 96: 14276-14281, 1999.
14. Damm, K., Hemmann, U., Garin-Chesa, P., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., Lauritsch, I., Muller, E., Pascolo, E., Sauter, G., Pantic, M., Martens, U. M., Wenz, C., Lingner, J., Kraut, N., Rettig, W. J., and Schnapp, A. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J., 20: 6958-6968, 2001.
15. Vonderheide, R. H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene, 21: 674-679, 2002.
16. Koga, S., Hirohata, S., Kondo, Y., Komata, T., Takakura, M., Inoue, M., Kyo, S., and Kondo, S. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum. Gene Ther., 11: 1397-1406, 2000.
17. Abdul-Ghani, R., Ohana, P., Matouk, I., Ayesh, S., Ayesh, B., Laster, M., Bibi, O., Giladi, H., Molnar-Kimber, K., Sughayer, M. A., de Groot, N., and Hochberg, A. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol. Ther., 2: 539-544, 2000.
18. Majumdar, A. S., Hughes, D. E., Lichtsteiner, S. P., Wang, Z., Lebkowski, J. S., and Vasserot, A. P. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther., 8: 568-578, 2001.
19. Plumb, J. A., Bilsland, A., Kakani, R., Zhao, J., Glasspool, R. M., Knox, R. J., Evans, T. R., and Keith, W. N. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB 1954. Oncogene, 20: 7797-7803, 2001.
20. Gu, J., Kagawa, S., Takakura, M., Kyo, S., Inoue, M., Roth, J. A., and Fang, B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res., 60: 5359-5364, 2000.
21. Huang, Q., Zhang, Z., Wang, H., Yan, B., Kirkpatrick, J., Dewhrist, M. W., and Li, C-Y. A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res., in press, 2004.
22. Lin, T., Huang, X., Gu, J., Zhang, L., Roth, J. A., Xiong, M., Curley, S. A., Yu, Y., Hunt, K. K., and Fang, B. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene, 21: 8020-8028, 2002.
23. Bilsland, A. E., Anderson, C. J., Fletcher-Monaghan, A. J., McGregor, F., Evans, T. R., Ganly, I., Knox, R. J., Plumb, J. A., and Keith, W. N. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene, 22: 370-380, 2003.
24. Kim, E., Kim, J. H., Shin, H. Y., Lee, H., Yang, J. M., Kim, J., Sohn, J. H., Kim, H., and Yun, C. O. Ad-mTERT-δ19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum. Gene Ther., 14: 1415-1428, 2003.
25. Kirch, H. C., Ruschen, S., Brockmann, D., Esche, H., Horikawa, I., Barrett, J. C., Opalka, B., and Hengge, U. R. Tumor-specific activation of hTERT-derived promoters by tumor suppressive E1A-mutants involves recruitment of p300/CBP/HAT and suppression of HDAC-1 and defines a combined tumor targeting and suppression system. Oncogene, 21: 7991-8000, 2002.